Itacitinib + Corticosteroid
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic and Lymphoid Cell Neoplasm
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Trial Timeline
Jan 30, 2025 → Apr 30, 2027
NCT ID
NCT05660421About Itacitinib + Corticosteroid
Itacitinib + Corticosteroid is a phase 2 stage product being developed by Johnson & Johnson for Hematopoietic and Lymphoid Cell Neoplasm. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05660421. Target conditions include Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm.
What happened to similar drugs?
1 of 3 similar drugs in Hematopoietic and Lymphoid Cell Neoplasm were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05660421 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Hematopoietic and Lymphoid Cell Neoplasm